Zhejiang Sunflower Great Health (300111.SZ): 0.167 billion shares of restricted shares will be lifted on September 18th.
Geelong on September 11th announced a notice about the lifting of the restricted shares of stocks issued to specific entities. The restricted shares being lifted this time are the stocks issued to specific entities, with a quantity of 0.167 billion shares, accounting for 13.01% of the company's current total share capital. The restricted shares will be listed for trading on September 18, 2024 (Wednesday).
Sunflowers: 2024 Semi-Annual Report
Sunflower: 2024 Semi-Annual Report Summary
Zhejiang Sunflower Great Health (300111.SZ): The net income in the first half of the year was 1.8045 million yuan, turning around from a loss on a year-on-year basis.
On August 28, Great Health (300111.SZ) released its semi-annual report for 2024, with a revenue of 0.158 billion yuan, a year-on-year increase of 4.80%; a net income of 1.8045 million yuan attributable to the company's shareholders, turning losses into profits year-on-year; a net income of 0.8093 million yuan attributable to the company's shareholders after deducting non-recurring gains and losses; and an earnings per share of 0.001 yuan.
Zhejiang Sunflower (300111.SZ) released its semi-annual performance with a net income of 1.8045 million yuan, which turned a loss into a profit on a year-on-year basis.
Zhejiang Sunflower Great Health (300111.SZ) disclosed its 2024 interim report, achieving revenue of...
Are Zhejiang Sunflower Great Health Co., Ltd.'s (SZSE:300111) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
Zhejiang Sunflower Great Health Co., Ltd.'s (SZSE:300111) Business Is Trailing The Industry But Its Shares Aren't
Sunflower (300111.SZ): Net profit of 551,000 yuan for the first quarter reversed the year-on-year loss
Gelonghui, April 26 | Sunflower (300111.SZ) released its report for the first quarter of 2024. Operating income for the reporting period was 83.6929 million yuan, up 36.57% year on year; net profit attributable to shareholders of listed companies was 551,000 yuan, which turned a year-on-year loss into a profit; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 4391,000 yuan; basic earnings per share were 0.0004 yuan.
Sunflower (300111.SZ) announced its 2023 annual results, turning a loss into a profit of 21.7479 million yuan
Sunflower (300111.SZ) released its 2023 annual report. The company's revenue was 338 million yuan,...
Declining Stock and Decent Financials: Is The Market Wrong About Zhejiang Sunflower Great Health Co., Ltd. (SZSE:300111)?
Aiskai (300521.SZ) shareholders added Orange Qiandao No. 1 Fund and Yanfeng Sunflower No. 1 Fund reduced their holdings by only 200 shares
Ascay (300521.SZ) announced that the company received “...” from the Tiancheng Qiandao No. 1 Fund and the Yanfeng Sunflower No. 1 Fund
Sunflower (300111.SZ): Proposed joint investment with related parties to establish a project company
Gelonghui (300111.SZ) announced that based on the strategic planning and business development of Zhejiang Sunflower Health Technology Co., Ltd. (hereinafter referred to as “Company” or “Party A”), the company signed an investment cooperation agreement with Zhuhai Youying New Materials Investment Partnership (Limited Partnership) (hereinafter referred to as “Youying New Materials” or “Party B”) and 2495 Metal-based Ceramic Technology (Zhuhai Hengqin) Partnership (Limited Partnership) (hereinafter referred to as “2495” or “Party C”) on March 1, 2024》It is proposed to jointly invest in the establishment of a limited liability company (hereinafter referred to as the “Project Company”
Sunflower (300111.SZ) Currently, there is no risk of liquidation of shares pledged by the company's actual controller
Gelonghui, Feb. 2: Sunflower (300111.SZ) said on the investor interactive platform that there is currently no risk of closing the shares pledged by the company's actual controller.
Sunflower (300111.SZ): Termination of TopCon battery product project and cancellation of project company
Gelonghui, February 2, 丨 Sunflower (300111.SZ) announced that the company held the 25th meeting of the 5th board of directors and the 18th meeting of the 5th board of supervisors on February 2, 2024 to review and pass the “Proposal on Termination of Investment Cooperation Agreements and Cancellation of Project Companies”. The company worked with Shanghai Longxiang Private Equity Fund Management Co., Ltd. (hereinafter referred to as “Shanghai Longxiang”) and Shanghai Longhe Enterprise Management Center (limited partnership) (hereinafter referred to as “Shanghai Longxiang”), Shaoxing Binhai New Area Integrated Circuit Industry Equity Investment Fund Partnership (hereinafter referred to as “Shanghai Longxiang”) Called “Shaoxing Integrated Circuit Fund”), Zhejiang
Zhejiang Sunflower Great Health Co., Ltd.'s (SZSE:300111) Popularity With Investors Is Under Threat From Overpricing
Sunflower (300111.SZ) issued a pre-profit and is expected to have a net profit of 19 million yuan to 27 million yuan in 2023, turning a loss into a profit
Sunflower (300111.SZ) disclosed its 2023 annual results forecast. The company is expected to belong to shareholders of listed companies...
Sunflower (300111.SZ) shareholder Wu Jianlong pledges 74 million shares
Sunflower (300111.SZ) announced that Wu Jianlong, the shareholder of the company, held 74 million shares of the company (...
Wu Jianlong, shareholder of Sunflower (300111.SZ), lifted the pledge of 74 million shares
Sunflower (300111.SZ) issued an announcement. The company recently received a notice from shareholder Wu Jianlong and learned that Wu Jianlong will...
Ascay (300521.SZ): Dongtian Orange Qiandao No. 1 Fund and Yanfeng Sunflower No. 1 Fund each plan to reduce their holdings by no more than 1%
Gelonghui, January 10 | Ascay (300521.SZ) announced that the shareholders of each holding 7,200,000 shares of the company (5% of the company's total share capital), Shanghai Tiancheng Investment Management Co., Ltd. (“Tianzheng Qiandao No. 1 Fund”) and Shanghai Yanfeng Investment Management Co., Ltd. [Daiyanfeng Sunflower No. 1 Private Equity Investment Fund (“Yanfeng Sunflower No. 1 Fund”)] plan to pass centralized bidding within three months of 15 trading days from the date of the announcement of the reduction plan Reduce your holdings by trading in bulk No more than the company's shares 1,4
[BT Financial Report Instantaneous Analysis] Sunflower 2023 Quarterly Report: Balance Sheet Optimization, Net Profit Turned Loss into Profit
This financial report was announced on 2023-10-27 18:40:56 Sunflower Company (stock code: 300111) is an enterprise focusing on R&D, production and sales of pharmaceutical products. The company belongs to the C27 pharmaceutical manufacturing industry. Its main products include anti-infective drugs, cardiovascular drugs, and digestive system drugs. In terms of APIs, the company is in a leading position in clarithromycin API production, and sells its products to many domestic pharmaceutical manufacturers as well as Japan, the United States, India, South Korea, Pakistan and other countries. In terms of pharmaceuticals, the company's products are listed as national medicine
No Data
No Data